MoonLake Immunotherapeutics AG

Planning for top-seller Jakafi’s (ruxolitinib) US patent expiration in 2028, Incyte reported positive top-line data from a pair of Phase III trials of selective JAK1 inhibitor povorcitinib in hidraden

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Pfizer/Arvinas’s VERITAC-2 Study Of Vepdegestrant In 2025, the first Phase III clinical readout for a PROTAC degrader is expected in an important milestone for the targeted protein degradation (TPD)

Pharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w